Collaborations and License Agreements - Additional Information (Detail)	1 Months Ended				3 Months Ended		12 Months Ended
	Apr. 30, 2016 USD ($)	Aug. 31, 2015 USD ($)	Nov. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2016 USD ($) Indication	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Apr. 30, 2014 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue					$ 1,203,000	$ 134,000
Amounts due from pursuant to the cost-sharing provisions					1,736,000		$ 4,641,000
Clinical Efficacy Milestone | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					$ 6,000,000
CANbridge
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date					Mar. 16, 2016
Collaborations and license agreements, milestone payment received					$ 0
Amounts due from pursuant to the cost-sharing provisions					900,000
CANbridge | Licensing Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable, net					100,000
Reimbursable amount for manufacturing costs and expenses.					$ 1,000,000
Collaborations and license agreements, time period from first commercial sale of certain product upon which the agreement expires					10 years
Collaborations and license agreements, written notice period for termination					30 days
Collaborations and license agreements, written notice period for termination other material breach					90 days
Collaborations and license agreements, written notice period for termination without cause					180 days
Allocation of upfront payment					$ 1,000,000
Collaboration revenue					1,000,000
CANbridge | Licensing Agreements | Subsequent Event
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable	$ 1,000,000
CANbridge | Licensing Agreements | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					90,000,000
CANbridge | Licensing Agreements | Development and Regulatory Milestone Events
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					$ 42,000,000
CANbridge | Licensing Agreements | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, written notice period for termination					45 days
CANbridge | Licensing Agreements | Due Within Twelve Months From Effective Date
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reimbursable amount for manufacturing costs and expenses.					$ 500,000
CANbridge | Licensing Agreements | Due Within Eighteen Months From Effective Date
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reimbursable amount for manufacturing costs and expenses.					$ 500,000
EUSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement date					Dec. 21, 2006
Collaborations and license agreements, expected milestone receivable					$ 4,000,000
Research and development funding received					2,500,000		2,500,000
Payments received in connection with indications					$ 2,000,000
Eligible number of indications | Indication					3
Payments received in connection with additional indications					$ 5,000,000
Potential payments received in connection with additional indications					335,000,000
Collaborations and license agreements, milestone payment received					100,000
EUSA | Utilization of Data Generated by Planned Phase Three Study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received					20,000,000
EUSA | Potential Phase One Combination Study
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received					2,000,000
EUSA | Marketing Approval in France, Germany, Italy, Spain and the United Kingdom
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received					2,000,000
EUSA | Marketing Approval in Argentina, Australia, Brazil, South Africa and Venezuela
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment to be received					$ 2,000,000
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable		$ 15,000,000
Period for payment of license fees					15 days
Reimbursable inventory		3,500,000
License and service revenue					$ 3,500,000
Amounts due from pursuant to the cost-sharing provisions					0
Novartis | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					150,000,000
Novartis | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					53,000,000
Novartis | Regulatory Milestone Events
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					105,000,000
Novartis | License and Technical Knowledge
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue							15,000,000
Pharmstandard
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable		1,500,000
Allocation of upfront payment					1,000,000
Collaboration revenue					$ 38,000
Period for payment of license fees					15 days
Upfront license payment							1,000,000
Pharmstandard | Receivable within fifteen business days of the date the license agreement is registered with the Federal Service for Intellectual Property of the Russian Federation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable							$ 500,000
Pharmstandard | Receivable With First Marketing Authorization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable		7,500,000
Pharmstandard | Receivable If Additional Regulatory Studies Required Prior To Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable		3,000,000
Pharmstandard | Receivable For Each Additional Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fees receivable		$ 3,000,000
Ophthotech Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
One time option exercise fee					$ 2,000,000
Ophthotech Corporation | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license payment			$ 500,000
License expiration period			2017-02
Collaborations and license agreements, payment received								$ 500,000
Collaborations and license agreements, revenue recognized					28,000	58,000
Ophthotech Corporation | Sales Based Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received					45,000,000
Ophthotech Corporation | Phase Two Clinical Trials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received					10,000,000
Ophthotech Corporation | Marketing Approval in the United States
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received					20,000,000
Ophthotech Corporation | Marketing Approval in the UK, Germany, Spain, Italy and France
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, milestone payment received					$ 20,000,000
Ophthotech Corporation | Clinical Efficacy Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, written notice period for termination					90 days
Ophthotech Corporation | Ind Submission Milestone Payment | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, expected milestone receivable					$ 2,000,000
Biodesix
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions					700,000
Biodesix | N S C L C P O C Trial
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions					700,000	900,000
Collaborations and license agreements, payment received					1,300,000	1,800,000
Responsible percentage of development and regulatory costs after cap reached									50.00%
Collaborations and license agreements, royalties payment on net sales									10.00%
Biodesix | N S C L C P O C Trial | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions					$ 900,000	900,000
Biodesix | N S C L C P O C Trial | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding									$ 15,000,000
St Vincent's Hospital Sydney Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amendment agreement date					2015-08
License fees payable					$ 18,900,000
Collaborations and license agreements, milestone payment					400,000
St Vincent's Hospital Sydney Limited | Licensing Agreements | Up-front Payment Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, cash payment					1,500,000
Biogen Idec International GmbH
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized				$ 14,100,000
Collaborations and license agreements, deferred revenue				14,700,000
Collaborations and license agreements, relative selling price of the deliverable				$ 600,000
Biogen Idec International GmbH | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty payments					50,000,000
Biogen Idec International GmbH | Option and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, revenue recognized					38,000	76,000
Astellas Pharma Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions					200,000
Astellas Pharma Inc. | Astellas Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amounts due from pursuant to the cost-sharing provisions					200,000	(200,000)
Astellas Pharma Inc. | Astellas Agreement | Research and development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received and recorded as an increased (decreased) to expense pursuant to cost-sharing provisions					(200,000)	200,000
Astellas Pharma Inc. | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborations and license agreements, payment received					$ 100,000	$ 500,000